SuperworthResMed profit margin RMD
Gross, operating and net profit as a share of revenue over the last twelve months, from 2010.
- Net margin, 12 months
- 26.9%
- Operating margin, 12 months
- 33.4%
- Net margin on a year earlier
- −0.3 pts
- Peer median
- 13.5%
Over the twelve months to Jun 30, 2026, ResMed kept 26.9% of its revenue as net profit, with an operating margin of 33.4% and a gross margin of 61.1%.
Five years earlier its net margin was 14.8%.
The median for 10 medical instruments and supplies stocks of a similar size is 13.5%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2026 | 26.9% | 33.4% | 61.1% |
| FY2025 | 27.2% | 32.7% | 59.4% |
| FY2024 | 21.8% | 28.2% | 56.7% |
| FY2023 | 21.3% | 26.8% | 55.8% |
| FY2022 | 21.8% | 28.0% | 56.6% |
| FY2021 | 14.8% | 28.3% | 57.5% |
| FY2020 | 21.0% | 27.4% | 58.1% |
| FY2019 | 15.5% | 22.2% | 58.2% |
| FY2018 | 13.5% | 23.2% | 58.2% |
| FY2017 | 16.6% | 20.6% | 58.1% |
| FY2016 | 19.2% | 23.3% | 58.0% |
| FY2015 | 21.0% | 24.4% | 60.2% |
| FY2014 | 22.2% | 26.1% | 63.7% |
| FY2013 | 20.3% | 23.4% | 62.1% |
| FY2012 | 18.6% | 21.5% | 60.0% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q4 FY26 | 26.9% | −0.3 pts | 33.4% | |
| Q3 FY26 | 27.4% | +1.3 pts | 34.2% | |
| Q2 FY26 | 27.5% | +2.2 pts | 33.7% | |
| Q1 FY26 | 27.4% | +4.2 pts | 33.2% | |
| Q4 FY25 | 27.2% | +5.4 pts | 32.7% | |
| Q3 FY25 | 26.2% | +5.2 pts | 32.1% | |
| Q2 FY25 | 25.3% | +5.6 pts | 31.7% | |
| Q1 FY25 | 23.1% | +2.4 pts | 29.5% | |
| Q4 FY24 | 21.8% | +0.5 pts | 28.2% | |
| Q3 FY24 | 20.9% | −0.6 pts | 26.5% | |
| Q2 FY24 | 19.8% | −1.7 pts | 25.3% | |
| Q1 FY24 | 20.7% | −1.0 pts | 26.2% |
Against its peers
Companies in Medical - Instruments & Supplies nearest ResMed's size, closest first, today.
| Company | Profit margin |
|---|---|
| RMDResMed | 26.9% |
| MDLNMedline | n/m |
| WSTWest Pharmaceutical Services | 17.0% |
| BDXBecton, Dickinson and | 4.5% |
| SOLVSolventum | 17.3% |
| PENPenumbra | 10.7% |
| COOCooper Companies | 13.5% |
| ALGNAlign Technology | 10.0% |
| GMEDGlobus Medical | 17.0% |
| PODDInsulet | 12.3% |
| ISRGIntuitive Surgical | 25.5% |
| Peer median | 13.5% |
Where ResMed ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on ResMed
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.